FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

			Washington, D.C. 20549	OMB APPROVAL						
to Secti	this box if no longer subject on 16. Form 4 or Form 5 ons may continue. See	STATEMEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP							
Instruct	ion 1(b).	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	4	<u>[[</u>	hours per respo		0.5		
	d Address of Reporting Pers <mark>Armand</mark>	on*	2. Issuer Name and Ticker or Trading Symbol <u>GLYCOMIMETICS INC</u> [GLYC]	tionship of R all applicable Director	Reporting Person(s) to Issuer le) 10% Owner					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	- x	Officer (giv below) SVP. Ch	e title ief Business	Other (spec below) Officer	ify		
C/O GLY	COMIMETICS INC				1 - C					

C/O GLYCOMIMETICS, INC. 9708 MEDICAL CENTER DRIVE	11/11/2022	SVF, Chief Dusiliess Officer
Street) ROCKVILLE MD 20850 City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	11/11/2022		Р		6,500	Α	\$1.05	29,161	D	

					_			<u> </u>	1						
		Ta	ble II - Derivat (e.g., pı					iired, Disp options, d					d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Remarks:

/s/ Brian F. Leaf, attorney-in-11/14/2022 <u>fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.